Board Expands From Five To Six Directors, CEO Dr. Cheng Liu Continues As Director
Estrella Immunopharma Appoints Hong Zhang As Chairperson And Board Member Following Dosing Of First Patient In Phase I/II Clinical Trial For EB103 T-Cell Therapy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.